Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

211At-NaAt

Radiopharmaceutical · developed by Alpha Fusion

Phase 1 Most advanced trial

ACOG Developer

1 Registered trials

What is 211At-NaAt?

211At-NaAt is an investigational radiopharmaceutical studied in DTC - Differentiated Thyroid Cancer.

At a glance

Also known as: [211At]NaAt
Drug type: Radiopharmaceutical
Therapy area: Oncology
Developer: Alpha Fusion Inc. (ACOG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07287748	Phase 1	DTC - Differentiated Thyroid Cancer	Recruiting	ACOG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DTC - Differentiated Thyroid Cancer

More from Alpha Fusion

Benzgalantamine FDA approved Zorifertinib Phase 2/3

Sources

ClinicalTrials.gov NCT07287748

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACOG page.

Follow ACOG, the company behind 211At-NaAt

See ACOG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACOG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z